CR20210548A - Materiales y métodos para modular la inmunidad mediada por células t - Google Patents

Materiales y métodos para modular la inmunidad mediada por células t

Info

Publication number
CR20210548A
CR20210548A CR20210548A CR20210548A CR20210548A CR 20210548 A CR20210548 A CR 20210548A CR 20210548 A CR20210548 A CR 20210548A CR 20210548 A CR20210548 A CR 20210548A CR 20210548 A CR20210548 A CR 20210548A
Authority
CR
Costa Rica
Prior art keywords
methods
modulating
materials
antibodies
cell mediated
Prior art date
Application number
CR20210548A
Other languages
English (en)
Inventor
Iqbal S Grewal
Sanjaya Singh
Rajkumar Ganesan
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CR20210548A publication Critical patent/CR20210548A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen anticuerpos anti-TRGV9 o fragmentos de unión al antígeno de estos. También se describen ácidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, métodos para producir los anticuerpos y métodos para usar los anticuerpos para tratar o prevenir enfermedades, tales como el cáncer.
CR20210548A 2019-05-08 2020-05-07 Materiales y métodos para modular la inmunidad mediada por células t CR20210548A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962844976P 2019-05-08 2019-05-08
US201962844995P 2019-05-08 2019-05-08
US201962844959P 2019-05-08 2019-05-08
US201962844966P 2019-05-08 2019-05-08
US201962844970P 2019-05-08 2019-05-08
PCT/US2020/031749 WO2020227457A1 (en) 2019-05-08 2020-05-07 Materials and methods for modulating t cell mediated immunity

Publications (1)

Publication Number Publication Date
CR20210548A true CR20210548A (es) 2022-02-11

Family

ID=73051172

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210548A CR20210548A (es) 2019-05-08 2020-05-07 Materiales y métodos para modular la inmunidad mediada por células t

Country Status (21)

Country Link
US (2) US11667712B2 (es)
EP (1) EP3965818A4 (es)
JP (1) JP2022533538A (es)
KR (1) KR20220017892A (es)
CN (1) CN113966231A (es)
AU (1) AU2020267504A1 (es)
BR (1) BR112021022089A2 (es)
CA (1) CA3139508A1 (es)
CL (1) CL2021002905A1 (es)
CO (1) CO2021015998A2 (es)
CR (1) CR20210548A (es)
DO (1) DOP2021000229A (es)
EC (1) ECSP21087921A (es)
IL (1) IL287817A (es)
JO (1) JOP20210297A1 (es)
MA (1) MA55903A (es)
MX (1) MX2021013532A (es)
PE (1) PE20220763A1 (es)
SG (1) SG11202112021QA (es)
TW (1) TW202108618A (es)
WO (1) WO2020227457A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2975078A1 (en) 2015-01-27 2016-08-04 Lava Therapeutics B.V. Single domain antibodies targeting cd1d
JP7457007B2 (ja) 2018-09-19 2024-03-27 ラヴァ・セラピューティクス・エヌ・ヴイ 二重作用ＣＤ１ｄ免疫グロブリン
JP2023515199A (ja) * 2020-02-27 2023-04-12 ヤンセン バイオテツク，インコーポレーテツド 免疫応答を調節するための材料及び方法
US20210284731A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
EP4237003A1 (en) 2020-10-28 2023-09-06 Janssen Biotech, Inc. Compositions and methods for modulating delta gamma chain mediated immunity
KR20230169950A (ko) 2021-02-26 2023-12-18 라바 테라퓨틱스 엔.브이. Cd123 및 감마-델타 t 세포 수용체에 결합하는 항체

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2003048328A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
MX2007002856A (es) 2004-09-02 2007-09-25 Genentech Inc Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
PL1999154T3 (pl) 2006-03-24 2013-03-29 Merck Patent Gmbh Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
EP2069401A4 (en) 2007-07-31 2011-02-23 Medimmune Llc MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
CN107385034B (zh) 2009-09-03 2021-08-17 弗·哈夫曼-拉罗切有限公司 用于治疗、诊断和监控类风湿性关节炎的方法
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
NZ607615A (en) 2010-08-05 2015-03-27 Anaptysbio Inc Antibodies directed against il-17
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
PT2773671T (pt) 2011-11-04 2021-12-14 Zymeworks Inc Geração de anticorpo heterodimérico estável com mutações no domínio fc
BR112014015018A2 (pt) * 2011-12-19 2020-10-27 Synimmune Gmbh moléculas de anticorpo biespecífico e seu método de produção, bem como composição farmacêutica e molécula de ácido nucleico
EP3060059A4 (en) * 2013-10-25 2017-11-01 Board of Regents, The University of Texas System Polyclonal gamma delta t cells for immunotherapy
MX2016013332A (es) 2014-04-10 2017-05-01 Stichting Vumc Receptores de células t vy9vd2 humanas que se unen a inmunoglobulinas.
WO2016196237A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
CN110536901B (zh) 2016-12-26 2024-06-18 协和麒麟株式会社 与髓鞘少突胶质细胞糖蛋白结合的抗体
US11236145B2 (en) * 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
WO2019147735A1 (en) * 2018-01-23 2019-08-01 New York University Antibodies specific to delta 1 chain of t cell receptor
JP2023515199A (ja) 2020-02-27 2023-04-12 ヤンセン バイオテツク，インコーポレーテツド 免疫応答を調節するための材料及び方法
US20210284731A1 (en) 2020-03-13 2021-09-16 Janssen Biotech, Inc. Methods and materials for modulating an immune response
EP4237003A1 (en) 2020-10-28 2023-09-06 Janssen Biotech, Inc. Compositions and methods for modulating delta gamma chain mediated immunity

Also Published As

Publication number Publication date
CL2021002905A1 (es) 2022-06-17
BR112021022089A2 (pt) 2022-02-08
DOP2021000229A (es) 2022-07-31
PE20220763A1 (es) 2022-05-16
CA3139508A1 (en) 2020-11-12
TW202108618A (zh) 2021-03-01
IL287817A (en) 2022-01-01
JOP20210297A1 (ar) 2023-01-30
ECSP21087921A (es) 2022-01-31
US20210032338A1 (en) 2021-02-04
US20240150464A1 (en) 2024-05-09
MX2021013532A (es) 2022-02-11
CN113966231A (zh) 2022-01-21
KR20220017892A (ko) 2022-02-14
AU2020267504A1 (en) 2021-12-02
WO2020227457A1 (en) 2020-11-12
US11667712B2 (en) 2023-06-06
MA55903A (fr) 2022-03-16
SG11202112021QA (en) 2021-11-29
EP3965818A4 (en) 2023-05-31
JP2022533538A (ja) 2022-07-25
CO2021015998A2 (es) 2021-12-10
EP3965818A1 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
JOP20210297A1 (ar) مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
PH12020552010A1 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
PH12020551907A1 (en) Antagonizing cd73 antibody
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
MX2022010664A (es) Materiales y métodos para modular una respuesta inmunitaria.
SA519402358B1 (ar) Ccr7 مترافقات عقار جسم مضاد لـ
SA522432139B1 (ar) بروتينات ربط متعددة الخصوصية لمعالجة السرطان
AU2019415848A8 (en) Claudin18.2 binding moieties and uses thereof
WO2019217145A8 (en) Anti-dll3 antibodies and uses thereof
MX2023002945A (es) Moléculas multiespecíficas con direccionamiento inmunitario y usos de estas.
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
MX2024002238A (es) Anticuerpos anti-ccr8 y uso de los mismos.
MX2021004454A (es) Anticuerpos anti-sinucleina.
CR20220505A (es) Anticuerpos anti-phf-tau y usos de estos
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
MX2023002948A (es) Métodos y composiciones para modular la inmunidad mediada por cadena beta.
MX2023011339A (es) Anticuerpos anti-tau y usos de estos.
WO2021058711A3 (en) Antigen binding proteins
MX2024005336A (es) Composiciones y metodos para la modulacion de inmunidad mediada por cadena beta.
EA202193035A1 (ru) Материалы и способы для модуляции иммунитета, опосредованного т-клетками
MX2024009326A (es) Anticuerpos anti-btla y usos de los mismos en el tratamiento del cancer.
EA202092121A1 (ru) Антитела против cd73 и их применения